Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best biotech stocks to buy according to Wall Street analysts.

Corcept Therapeutics (CORT) is back on investors radar after fresh analyst commentary spotlighted its pipeline, particularly relacorilant, ahead of a key PDUFA decision for Cushing’s syndrome later ...

On December 4, a recent SEC filing unveiled that William Guyer, Chief Development Officer at Corcept Therapeutics (NASDAQ: CORT) made an insider sell.

Corcept Therapeutics (NASDAQ:CORT) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release. Analysts are ...

Corcept Therapeutics CORT has been making meaningful progress with its sole-marketed drug, Korlym (mifepristone), which is ...

While sales of its flagship product, Korlym, grew about 14% year-over-year to $207.6 million, Corcept revised its full-year 2025 revenue guidance downward to a range of $800–850 million, from a prior ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the best stocks you’ll wish you bought sooner. As of the close of December 2, the consensus shows that analyst opinions are highly favourable ...

Corcept Therapeutics (CORT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 22. Analyst Roanna Ruiz from Leerink Partners remains neutral on the ...

Across the recent three months, 7 analysts have shared their insights on Corcept Therapeutics (NASDAQ:CORT), expressing a variety of opinions spanning from bullish to bearish. The following table ...

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a ...

Revenue of $123.6 million, a 22 percent increase from third quarter 2022 Increase in 2023 revenue guidance to $470 - $480 million, from $455 - $470 million Net income per common share of $0.28 ...

Revenue of $163.8 million, a 39 percent increase over the same period in 2023 Increase in 2024 revenue guidance to $640 – $670 million, from $620 – $650 million Net income per common share of $0.32 ...